{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:34:06Z","timestamp":1783575246703,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000085","name":"Ontario HIV Treatment Network","doi-asserted-by":"publisher","award":["Junior Investigator Development Award"],"award-info":[{"award-number":["Junior Investigator Development Award"]}],"id":[{"id":"10.13039\/501100000085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01HD104553"],"award-info":[{"award-number":["R01HD104553"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01HD104553"],"award-info":[{"award-number":["R01HD104553"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01HD104553"],"award-info":[{"award-number":["R01HD104553"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01HD104553"],"award-info":[{"award-number":["R01HD104553"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01HD104553"],"award-info":[{"award-number":["R01HD104553"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["Maternal-Child Health and HIV"],"award-info":[{"award-number":["Maternal-Child Health and HIV"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-02130-8","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T09:28:12Z","timestamp":1749029292000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of dolutegravir-based antiretroviral therapy on glycemic control in female mice"],"prefix":"10.1038","volume":"15","author":[{"given":"Valeriya","family":"Dontsova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haneesha","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maisha","family":"Fahmida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D. E.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Copp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Zash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Jao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Serghides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"2130_CR1","doi-asserted-by":"publisher","first-page":"e809","DOI":"10.1016\/S2352-3018(19)30230-9","volume":"6","author":"A Pandey","year":"2019","unstructured":"Pandey, A. & Galvani, A. P. The global burden of HIV and prospects for control. Lancet HIV. 6, e809\u2013e811 (2019).","journal-title":"Lancet HIV."},{"key":"2130_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2022.22246","volume":"329","author":"RT Gandhi","year":"2023","unstructured":"Gandhi, R. T. et al. Antiretroviral drugs for treatment and prevention of hiv infection in adults: 2022 recommendations of the international antiviral society-USA panel. JAMA 329, 63\u201384 (2023).","journal-title":"JAMA"},{"key":"2130_CR3","volume-title":"testing, treatment, service delivery and monitoring: recommendations for a public health approach","author":"Consolidated guidelines on HIV prevention","year":"2021","unstructured":"Consolidated guidelines on HIV prevention. testing, treatment, service delivery and monitoring: recommendations for a public health approach (World Health Organization, 2021)."},{"key":"2130_CR4","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1056\/NEJMc1807653","volume":"379","author":"R Zash","year":"2018","unstructured":"Zash, R., Makhema, J. & Shapiro, R. L. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl. J. Med. 379, 979\u2013981 (2018).","journal-title":"N Engl. J. Med."},{"key":"2130_CR5","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1056\/NEJMoa1905230","volume":"381","author":"R Zash","year":"2019","unstructured":"Zash, R. et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl. J. Med. 381, 827\u2013840 (2019).","journal-title":"N Engl. J. Med."},{"key":"2130_CR6","unstructured":"Zash R, Holmes LB, Diseko M, Jacobson DL, Mayondi G, Mabuta J, et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo Study, Botswana. In 2022. Available from: https:\/\/programme.aids2022.org\/Abstract\/Abstract\/?abstractid=12759"},{"key":"2130_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103167","volume":"63","author":"H Mohan","year":"2021","unstructured":"Mohan, H. et al. Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels. EBioMedicine 63, 103167 (2021).","journal-title":"EBioMedicine"},{"key":"2130_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104762","volume":"95","author":"H Mohan","year":"2023","unstructured":"Mohan, H. et al. Folate deficiency increases the incidence of dolutegravir-associated foetal defects in a mouse pregnancy model. EBioMedicine 95, 104762 (2023).","journal-title":"EBioMedicine"},{"key":"2130_CR9","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S1474-4422(13)70110-8","volume":"12","author":"AJ Copp","year":"2013","unstructured":"Copp, A. J., Stanier, P. & Greene, N. D. E. Neural tube defects: recent advances, unsolved questions, and controversies. Lancet Neurol. 12, 799\u2013810 (2013).","journal-title":"Lancet Neurol."},{"key":"2130_CR10","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1001\/jama.2009.113","volume":"301","author":"KJ Stothard","year":"2009","unstructured":"Stothard, K. J., Tennant, P. W. G., Bell, R. & Rankin, J. Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis. JAMA 301, 636\u2013650 (2009).","journal-title":"JAMA"},{"key":"2130_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S2213-8587(20)30406-X","volume":"9","author":"HR Murphy","year":"2021","unstructured":"Murphy, H. R. et al. Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: A 5-year national population-based cohort study. Lancet Diabetes Endocrinol. 9, 153\u2013164 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2130_CR12","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.bbrc.2022.11.029","volume":"637","author":"M Dom\u00ednguez-Castro","year":"2022","unstructured":"Dom\u00ednguez-Castro, M. et al. Hyperglycemia affects neuronal differentiation and Nestin, FOXO1, and LMO3 mRNA expression of human Wharton\u2019s jelly mesenchymal stem cells of children from diabetic mothers. Biochem. Biophys. Res. Commun. 637, 300\u2013307 (2022).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2130_CR13","first-page":"908","volume":"66","author":"CA Negrato","year":"2022","unstructured":"Negrato, C. A. et al. Glycemic and nonglycemic mechanisms of congenital malformations in hyperglycemic pregnancies: A narrative review. Arch. Endocrinol. Metab. 66, 908\u2013918 (2022).","journal-title":"Arch. Endocrinol. Metab."},{"key":"2130_CR14","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciz999","volume":"71","author":"PE Sax","year":"2020","unstructured":"Sax, P. E. et al. Weight gain following initiation of antiretroviral therapy: Risk factors in randomized comparative clinical trials. Clin. Infect Dis. Off Publ. Infect. Dis. Soc. Am. 71, 1379\u20131389 (2020).","journal-title":"Clin. Infect Dis. Off Publ. Infect. Dis. Soc. Am."},{"key":"2130_CR15","doi-asserted-by":"publisher","first-page":"ciae191","DOI":"10.1093\/cid\/ciae191","volume":"79","author":"DA Wohl","year":"2024","unstructured":"Wohl, D. A. et al. Antiretrovirals and weight change: Weighing the evidence. Clin. Infect Dis. Off Publ. Infect. Dis. Soc. Am. 79, ciae191 (2024).","journal-title":"Clin. Infect Dis. Off Publ. Infect. Dis. Soc. Am."},{"key":"2130_CR16","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1097\/QAD.0000000000001495","volume":"31","author":"A Menard","year":"2017","unstructured":"Menard, A. et al. Dolutegravir and weight gain: an unexpected bothering side effect?. AIDS Lond. Engl. 31, 1499\u20131500 (2017).","journal-title":"AIDS Lond. Engl."},{"key":"2130_CR17","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1177\/09564624221129410","volume":"33","author":"D Namara","year":"2022","unstructured":"Namara, D. et al. The risk of hyperglycemia associated with use of dolutegravir among adults living with HIV in Kampala, Uganda: A case-control study. Int. J. STD AIDS. 33, 1158\u20131164 (2022).","journal-title":"Int. J. STD AIDS."},{"key":"2130_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X221079444","author":"AT Hirigo","year":"2022","unstructured":"Hirigo, A. T., Gutema, S., Eifa, A. & Ketema, W. Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus. SAGE Open Med. Case Rep. https:\/\/doi.org\/10.1177\/2050313X221079444 (2022).","journal-title":"SAGE Open Med. Case Rep."},{"key":"2130_CR19","first-page":"503","volume":"14","author":"W Hailu","year":"2021","unstructured":"Hailu, W., Tesfaye, T. & Tadesse, A. Hyperglycemia after dolutegravir-based antiretroviral therapy. Int. Med. Case Rep. J. 14, 503\u2013507 (2021).","journal-title":"Int. Med. Case Rep. J."},{"key":"2130_CR20","doi-asserted-by":"publisher","first-page":"e461","DOI":"10.1016\/S2352-3018(20)30042-4","volume":"7","author":"M Lamorde","year":"2020","unstructured":"Lamorde, M. et al. Dolutegravir-associated hyperglycaemia in patients with HIV. Lancet HIV. 7, e461\u2013e462 (2020).","journal-title":"Lancet HIV."},{"key":"2130_CR21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/jac\/dkx365","volume":"73","author":"M McLaughlin","year":"2018","unstructured":"McLaughlin, M., Walsh, S. & Galvin, S. Dolutegravir-induced hyperglycaemia in a patient living with HIV. J Antimicrob. Chemother. 73, 258\u2013260 (2018).","journal-title":"J Antimicrob. Chemother."},{"key":"2130_CR22","first-page":"17","volume":"16","author":"NC Waritu","year":"2024","unstructured":"Waritu, N. C. et al. Serum lipid profiles, blood glucose, and high-sensitivity C-reactive protein levels among people living with HIV taking dolutegravir and ritonavir-boosted atazanavir-based antiretroviral therapy at Jimma university medical Center, Southwest Ethiopia, 2021. HIVAIDS Auckl NZ. 16, 17\u201332 (2024).","journal-title":"HIVAIDS Auckl NZ."},{"key":"2130_CR23","doi-asserted-by":"publisher","first-page":"2295435","DOI":"10.1080\/07853890.2023.2295435","volume":"55","author":"M Jemal","year":"2023","unstructured":"Jemal, M., Shibabaw Molla, T., Tiruneh G Medhin, M., Chekol Abebe, E. & Asmamaw, D. T. Blood glucose level and serum lipid profiles among people living with HIV on dolutegravir-based versus efavirenz-based cART; a comparative cross-sectional study. Ann. Med. 55, 2295435 (2023).","journal-title":"Ann. Med."},{"key":"2130_CR24","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/jac\/dky507","volume":"74","author":"L Calza","year":"2019","unstructured":"Calza, L. et al. Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients. J. Antimicrob. Chemother. 74, 731\u2013738 (2019).","journal-title":"J. Antimicrob. Chemother."},{"key":"2130_CR25","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1093\/jac\/dkaa330","volume":"75","author":"A Ursenbach","year":"2020","unstructured":"Ursenbach, A. et al. Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study. J Antimicrob. Chemother. 75, 3344\u20133348 (2020).","journal-title":"J Antimicrob. Chemother."},{"key":"2130_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/QAD.0000000000002718","volume":"35","author":"R Hsu","year":"2021","unstructured":"Hsu, R. et al. Incident type 2 diabetes mellitus after initiation of common HIV antiretroviral drugs. AIDS Lond. Engl. 35, 81\u201390 (2021).","journal-title":"AIDS Lond. Engl."},{"key":"2130_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025236","volume":"100","author":"BM Hamooya","year":"2021","unstructured":"Hamooya, B. M. et al. Metabolic syndrome in Zambian adults with human immunodeficiency virus on antiretroviral therapy: Prevalence and associated factors. Medicine (Baltimore) 100, e25236 (2021).","journal-title":"Medicine (Baltimore)"},{"key":"2130_CR28","doi-asserted-by":"publisher","first-page":"e606","DOI":"10.1016\/S2352-3018(23)00141-8","volume":"10","author":"V Dontsova","year":"2023","unstructured":"Dontsova, V. et al. Metabolic implications and safety of dolutegravir use in pregnancy. Lancet HIV. 10, e606\u2013e616 (2023).","journal-title":"Lancet HIV."},{"key":"2130_CR29","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1093\/cid\/ciaa259","volume":"71","author":"J Gorwood","year":"2020","unstructured":"Gorwood, J. et al. The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human\/simian adipose tissue and human adipocytes. Clin. Infect. Dis. 71, e549\u2013e560 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"2130_CR30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/infdis\/jiac175","volume":"226","author":"I Jung","year":"2022","unstructured":"Jung, I. et al. Dolutegravir suppresses thermogenesis via disrupting UCP1 expression and mitochondrial function in brown\/beige adipocytes in preclinical models. J. Infect. Dis. 226, 175 (2022).","journal-title":"J. Infect. Dis."},{"key":"2130_CR31","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.3390\/cells11111841","volume":"11","author":"K Ngono Ayissi","year":"2022","unstructured":"Ngono Ayissi, K. et al. Inhibition of adipose tissue beiging by hiv integrase inhibitors, dolutegravir and bictegravir, is associated with adipocyte hypertrophy, hypoxia, elevated fibrosis, and insulin resistance in simian adipose tissue and human adipocytes. Cells 11, 1841 (2022).","journal-title":"Cells"},{"key":"2130_CR32","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1159\/000445655","volume":"39","author":"A Al Mamun Bhuyan","year":"2016","unstructured":"Al Mamun Bhuyan, A., Signoretto, E., Bissinger, R. & Lang, F. Enhanced eryptosis following exposure to dolutegravir. Cell Physiol. Biochem. Int. J. Exp. Cell Physiol. Biochem. Pharmacol. 39, 639\u2013650 (2016).","journal-title":"Cell Physiol. Biochem. Int. J. Exp. Cell Physiol. Biochem. Pharmacol."},{"key":"2130_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.639378","volume":"12","author":"JW George","year":"2021","unstructured":"George, J. W. et al. Physiologically relevant concentrations of dolutegravir, emtricitabine, and efavirenz induce distinct metabolic alterations in hela epithelial and BV2 microglial cells. Front. Immunol. 12, 639378 (2021).","journal-title":"Front. Immunol."},{"key":"2130_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.antiviral.2018.09.008","volume":"159","author":"S Kala","year":"2018","unstructured":"Kala, S. et al. Improving the clinical relevance of a mouse pregnancy model of antiretroviral toxicity; a pharmacokinetic dosing-optimization study of current HIV antiretroviral regimens. Antiviral Res. 159, 45\u201354 (2018).","journal-title":"Antiviral Res."},{"key":"2130_CR35","first-page":"56672","volume":"131","author":"C Nagy","year":"2018","unstructured":"Nagy, C. & Einwallner, E. Study of in vivo glucose metabolism in high-fat diet-fed mice using oral glucose tolerance test (OGTT) and insulin tolerance test (ITT). J. Vis. Exp. JoVE. 131, 56672 (2018).","journal-title":"J. Vis. Exp. JoVE."},{"key":"2130_CR36","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","volume":"55","author":"SA Bustin","year":"2009","unstructured":"Bustin, S. A. et al. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55, 611\u2013622 (2009).","journal-title":"Clin. Chem."},{"key":"2130_CR37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2018069118","volume":"118","author":"I Darlyuk-Saadon","year":"2021","unstructured":"Darlyuk-Saadon, I. et al. Active p38\u03b1 causes macrovesicular fatty liver in mice. Proc. Natl. Acad. Sci. U S A. 118, e2018069118 (2021).","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"2130_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.116010","volume":"220","author":"T Quesada-L\u00f3pez","year":"2024","unstructured":"Quesada-L\u00f3pez, T. et al. Divergent effects of the antiretroviral drugs, dolutegravir, tenofovir alafenamide, and tenofovir disoproxil fumarate, on human adipocyte function. Biochem. Pharmacol. 220, 116010 (2024).","journal-title":"Biochem. Pharmacol."},{"key":"2130_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.lfs.2015.02.008","volume":"140","author":"G Fern\u00e1ndez-Formoso","year":"2015","unstructured":"Fern\u00e1ndez-Formoso, G., P\u00e9rez-Sieira, S., Gonz\u00e1lez-Touceda, D., Dieguez, C. & Tovar, S. Leptin, 20 years of searching for glucose homeostasis. Life Sci. 140, 4\u20139 (2015).","journal-title":"Life Sci."},{"key":"2130_CR40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.2040-1124.2012.00203.x","volume":"3","author":"HC Denroche","year":"2012","unstructured":"Denroche, H. C., Huynh, F. K. & Kieffer, T. J. The role of leptin in glucose homeostasis. J. Diabetes Investig. 3, 115\u2013129 (2012).","journal-title":"J. Diabetes Investig."},{"key":"2130_CR41","doi-asserted-by":"publisher","first-page":"e471","DOI":"10.1093\/cid\/ciaa177","volume":"71","author":"JE Lake","year":"2020","unstructured":"Lake, J. E. et al. Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 71, e471\u2013e477 (2020).","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"2130_CR42","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12981-024-00615-6","volume":"21","author":"I Nakatudde","year":"2024","unstructured":"Nakatudde, I. et al. Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala Uganda. AIDS Res Ther. 21, 23 (2024).","journal-title":"AIDS Res Ther."},{"key":"2130_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2024.107288","volume":"155","author":"TC Kress","year":"2024","unstructured":"Kress, T. C. et al. 12-week Dolutegravir treatment marginally reduces energy expenditure but does not increase body weight or alter vascular function in a murine model of Human Immunodeficiency Virus infection. Vascul Pharmacol. 155, 107288 (2024).","journal-title":"Vascul Pharmacol."},{"key":"2130_CR44","doi-asserted-by":"publisher","first-page":"e25702","DOI":"10.1002\/jia2.25702","volume":"24","author":"PW Mallon","year":"2021","unstructured":"Mallon, P. W. et al. Weight gain before and after switch from TDF to TAF in a U.S. cohort study. J. Int. AIDS Soc. 24, e25702 (2021).","journal-title":"J. Int. AIDS Soc."},{"issue":"92","key":"2130_CR45","first-page":"67","volume":"2023","author":"FJ Palella","year":"1999","unstructured":"Palella, F. J. et al. Weight gain and metabolic effects in persons with HIV who switch to ART regimens containing integrase inhibitors or tenofovir alafenamide. J. Acquir. Immune Defic. Syndr. 2023(92), 67\u201375 (1999).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"2130_CR46","doi-asserted-by":"publisher","first-page":"1133556","DOI":"10.3389\/frph.2023.1133556","volume":"5","author":"T Tovar Sanchez","year":"2023","unstructured":"Tovar Sanchez, T. et al. Risks of metabolic syndrome in the ADVANCE and NAMSAL trials. Front. Reprod. Health. 5, 1133556 (2023).","journal-title":"Front. Reprod. Health."},{"key":"2130_CR47","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1093\/cid\/ciac355","volume":"75","author":"JA O\u2019Halloran","year":"2022","unstructured":"O\u2019Halloran, J. A. et al. Integrase strand transfer inhibitors are associated with incident diabetes mellitus in people with human immunodeficiency virus. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 75, 2060\u20132065 (2022).","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"2130_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12981-023-00510-6","volume":"20","author":"F Mulindwa","year":"2023","unstructured":"Mulindwa, F. et al. Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir. AIDS Res. Ther. 20, 15 (2023).","journal-title":"AIDS Res. Ther."},{"key":"2130_CR49","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12981-023-00564-6","volume":"20","author":"F Mulindwa","year":"2023","unstructured":"Mulindwa, F. et al. Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults. AIDS Res. Ther. 20, 65 (2023).","journal-title":"AIDS Res. Ther."},{"key":"2130_CR50","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.3390\/nu11112704","volume":"11","author":"AG Izquierdo","year":"2019","unstructured":"Izquierdo, A. G., Crujeiras, A. B., Casanueva, F. F. & Carreira, M. C. Leptin, obesity, and leptin resistance: Where are we 25 years later?. Nutrients 11, 2704 (2019).","journal-title":"Nutrients"},{"key":"2130_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/endrev\/bnaa027","volume":"42","author":"S Pereira","year":"2021","unstructured":"Pereira, S., Cline, D. L., Glavas, M. M., Covey, S. D. & Kieffer, T. J. Tissue-specific effects of leptin on glucose and lipid metabolism. Endocr. Rev. 42, 1\u201328 (2021).","journal-title":"Endocr. Rev."},{"key":"2130_CR52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-1-4939-2895-8_5","volume":"872","author":"T Kuo","year":"2015","unstructured":"Kuo, T., McQueen, A., Chen, T. C. & Wang, J. C. Regulation of glucose homeostasis by glucocorticoids. Adv. Exp. Med. Biol. 872, 99\u2013126 (2015).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2130_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.836058","volume":"12","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Acetyl-CoA carboxylases and diseases. Front. Oncol. 12, 836058 (2022).","journal-title":"Front. Oncol."},{"key":"2130_CR54","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.161282","volume":"8","author":"T Matsukawa","year":"2023","unstructured":"Matsukawa, T. et al. Hepatic FASN deficiency differentially affects nonalcoholic fatty liver disease and diabetes in mouse obesity models. JCI Insight. 8, e161282 (2023).","journal-title":"JCI Insight."},{"key":"2130_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229617","volume":"15","author":"C McMahon","year":"2020","unstructured":"McMahon, C. et al. Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight. PLoS ONE 15, e0229617 (2020).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02130-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02130-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02130-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T22:01:23Z","timestamp":1749420083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02130-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2130"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-02130-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"2 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19601"}}